{
    "nctId": "NCT05851677",
    "briefTitle": "RC48-ADC in Breast Cancer",
    "officialTitle": "Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real World Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "Progression-Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed breast cancer;\n* Prior or current use of Disitamab vedotin (RC48-ADC);\n\nExclusion Criteria:\n\n* Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}